Nasal spray COVID treatment trial halted early
NCT ID NCT05541510
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 28 times
Summary
This study tested an intranasal spray called AD17002 in adults aged 18 to 65 with mild to moderate COVID-19. Participants received standard care plus either a placebo or one of two doses of the spray. The goal was to see if the spray could speed up recovery and improve symptoms. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
RSA UGM
Yogyakarta, Special Region of Yogyakarta, 55281, Indonesia
-
RSDC Wisma Atlit
Kota Jkt Utara, DKI Jakarta, 14360, Indonesia
-
RSPI Sulianti Saroso
Kota Jkt Utara, DKI Jakarta, 14340, Indonesia
Conditions
Explore the condition pages connected to this study.